SEPTIN4 and melanoma: Similarly, the HLA-DR4-restricted peptide MART-151–73 (RNGYRALMDKSLHVGTQCALTRR) has been shown to induce high CD4+ T cell responses in conjunction with the class I peptide MART-127–35 within melanoma patients [25].